| Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy (NCT00606216) | Memorial Sloan Kettering Cancer Center | 2007-01-01 |
| Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) (NCT00412360) | Medical College of Wisconsin | 2006-12-01 |
| Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) (NCT00414310) | M.D. Anderson Cancer Center | 2006-12-01 |
| Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia (NCT00392353) | National Cancer Institute (NCI) | 2006-11-22 |
| Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections (NCT00418951) | M.D. Anderson Cancer Center | 2006-11-01 |
| Combined Haploidentical-Cord Blood Transplantation for Adults and Children (NCT00943800) | University of Chicago | 2006-10-09 |
| A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome (NCT00282399) | Eisai Inc. | 2006-10-01 |
| Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD) (NCT00506948) | M.D. Anderson Cancer Center | 2006-09-01 |
| Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies (NCT00460694) | Singapore General Hospital | 2006-08-01 |
| Collection of Tissue Samples for Cancer Research (NCT00900198) | National Cancer Institute (NCI) | 2006-07-06 |
| PR1 Vaccination in Myelodysplastic Syndrome (MDS) (NCT00893997) | M.D. Anderson Cancer Center | 2006-07-01 |
| Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) (NCT00689000) | Chroma Therapeutics | 2006-05-01 |
| Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (NCT00402558) | M.D. Anderson Cancer Center | 2006-05-01 |
| Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) (NCT00525746) | M.D. Anderson Cancer Center | 2006-03-31 |
| T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation (NCT00306332) | Radboud University Medical Center | 2006-03-01 |
| A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy (NCT00597519) | Memorial Sloan Kettering Cancer Center | 2006-03-01 |
| Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients. (NCT01039350) | Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon | 2006-02-01 |
| Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) (NCT00285259) | Astellas Pharma Inc | 2006-01-31 |
| 2 Arm Study of Clofarabine IV in MDS Patients (NCT00422032) | M.D. Anderson Cancer Center | 2006-01-01 |
| Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies (NCT00270881) | Keio University | 2006-01-01 |
| A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (NCT00324220) | Mirati Therapeutics Inc. | 2006-01-01 |
| Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) (NCT00569010) | M.D. Anderson Cancer Center | 2005-12-01 |
| Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (NCT00719888) | Fred Hutchinson Cancer Center | 2005-11-18 |
| A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT00283114) | Seagen Inc. | 2005-11-01 |
| Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT) (NCT00350818) | M.D. Anderson Cancer Center | 2005-10-01 |
| Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (NCT00598624) | IRCCS San Raffaele | 2005-09-01 |
| Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients (NCT00382590) | M.D. Anderson Cancer Center | 2005-08-01 |
| Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies (NCT00143559) | St. Jude Children's Research Hospital | 2005-08-01 |
| Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients (NCT00110266) | Novartis Pharmaceuticals | 2005-07-25 |
| Phase II 5-Azacytidine Plus VPA Plus ATRA (NCT00326170) | M.D. Anderson Cancer Center | 2005-07-01 |
| Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies (NCT00672165) | Memorial Sloan Kettering Cancer Center | 2005-07-01 |
| Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome (NCT00760084) | Eisai Inc. | 2005-07-01 |
| Study of Velcade and Thalidomide in Patients With Myelodysplasia (NCT00271804) | Massachusetts General Hospital | 2005-06-01 |
| IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome (NCT00469144) | M.D. Anderson Cancer Center | 2005-06-01 |
| Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome (NCT00806598) | M.D. Anderson Cancer Center | 2005-05-01 |
| A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes (NCT00260065) | Eisai Inc. | 2005-05-01 |
| Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure (NCT00113321) | M.D. Anderson Cancer Center | 2005-03-01 |
| MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (NCT00101179) | National Cancer Institute (NCI) | 2004-11-03 |
| Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS) (NCT01062490) | medac GmbH | 2004-11-01 |
| A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome (NCT00251511) | Veeda Oncology | 2004-08-01 |
| To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning (NCT00226512) | Hadassah Medical Organization | 2004-07-01 |
| Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). (NCT00088218) | M.D. Anderson Cancer Center | 2004-07-01 |
| Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS (NCT00520468) | M.D. Anderson Cancer Center | 2004-06-01 |
| Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients (NCT00504920) | M.D. Anderson Cancer Center | 2004-05-01 |
| Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML (NCT00669890) | New York Medical College | 2004-05-01 |
| Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT00459524) | M.D. Anderson Cancer Center | 2004-04-01 |
| Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor (NCT00304720) | Colorado Blood Cancer Institute | 2004-03-01 |
| Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers (NCT00089596) | ViaCell | 2004-03-01 |
| Post Transplant Donor Lymphocyte Infusion (NCT00167180) | Masonic Cancer Center, University of Minnesota | 2004-01-01 |
| Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) (NCT00067028) | M.D. Anderson Cancer Center | 2003-12-01 |
| Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) (NCT00067808) | M.D. Anderson Cancer Center | 2003-10-01 |
| Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML (NCT00195104) | Weill Medical College of Cornell University | 2003-09-17 |
| AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) (NCT00071006) | Pfizer | 2003-09-01 |
| Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS (NCT00195000) | Weill Medical College of Cornell University | 2003-05-01 |
| Phase I Study of Sequential Cord Blood Transplants (NCT00299767) | Massachusetts General Hospital | 2003-05-01 |
| Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders (NCT00533923) | Beth Israel Deaconess Medical Center | 2002-12-01 |
| High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML (NCT00774046) | University of Chicago | 2002-12-01 |
| Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS) (NCT00057031) | Novacea | 2002-11-01 |
| Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies (NCT00113646) | Massachusetts General Hospital | 2002-11-01 |
| Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia (NCT01020539) | Columbia University | 2002-09-11 |
| Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation (NCT00144703) | Dana-Farber Cancer Institute | 2002-07-01 |
| Study of Gelonin Purging of Autologous Stem Cells for Transplantation (NCT00043810) | M.D. Anderson Cancer Center | 2002-07-01 |
| Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS) (NCT00050154) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2002-07-01 |
| A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. (NCT00300664) | Royal Marsden NHS Foundation Trust | 2002-07-01 |
| Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen (NCT00774280) | Cooperative Study Group A for Hematology | 2002-05-01 |
| Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome (NCT00488436) | PETHEMA Foundation | 2002-05-01 |
| Stem Cell Transplantation for Patients With Hematologic Malignancies (NCT00152139) | St. Jude Children's Research Hospital | 2002-05-01 |
| Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) (NCT00064584) | Millennium Pharmaceuticals, Inc. | 2002-05-01 |
| WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) (NCT00153582) | Charite University, Berlin, Germany | 2002-04-01 |
| Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome (NCT00044382) | Celgene | 2002-02-01 |
| Nonmyeloablative Allogeneic Transplant (NCT01272817) | Scripps Health | 2001-10-01 |
| Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes (NCT00045786) | Celgene | 2001-10-01 |
| Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders (NCT00587054) | Memorial Sloan Kettering Cancer Center | 2001-06-01 |
| Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS (NCT00038831) | M.D. Anderson Cancer Center | 2001-05-01 |
| Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor (NCT00582933) | Memorial Sloan Kettering Cancer Center | 2001-05-01 |
| Decitabine Versus Supportive Care in Adults With Advanced-stage MDS (NCT00043381) | Astex Pharmaceuticals, Inc. | 2001-04-01 |
| Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies (NCT00013533) | National Cancer Institute (NCI) | 2001-03-14 |
| Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia (NCT00005937) | Neal Young, M.D. | 2000-06-01 |
| T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts (NCT00368355) | Baylor College of Medicine | 2000-04-01 |
| Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow (NCT00003838) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-04-15 |
| The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers (NCT00001873) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-02-22 |
| SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia (NCT00487448) | PETHEMA Foundation | 1998-07-01 |
| L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes (NCT00329498) | Samsung Medical Center | 1998-05-01 |
| Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults (NCT00001637) | National Heart, Lung, and Blood Institute (NHLBI) | 1997-09-29 |
| A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (NCT00136461) | Dana-Farber Cancer Institute | 1997-05-01 |
| Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia (NCT00001623) | National Heart, Lung, and Blood Institute (NHLBI) | 1997-03-27 |
| Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation (NCT01020175) | European Society for Blood and Marrow Transplantation | 1995-01-01 |
| Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation (NCT02258490) | Emory University | |
| Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies (NCT07346105) | Orca Biosystems, Inc. | |
| Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant (NCT01200017) | Christopher Dvorak | |
| Expanded Access for ACE-011 (NCT03724227) | Celgene | |
| NOV-002 in Myelodysplastic Syndrome (MDS) (NCT00960726) | M.D. Anderson Cancer Center | |